VYNDAQEL are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid Meglumine
Vyndaqel
Transthyretin amyloidosis
Solid
Nuray’s expertise and experience lie in developing pharmaceutical industry’s chemistry requirements from the synthesis of NCEs,
Plot No.111, SIDCO Industrial Estate, Kakkalur, Thiruvallur 602 003 Tamilnadu, India.
044 66616700
044 35016700
+1(609)721-8261
Business - enquiry@nuraychemicals.com
Nuraychemicals is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2012 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.